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Background: Recent observational studies suggest a role for lipopolysaccharide (LPS) as a marker of immune
activation in HIV-infected patients, with potential repercussions on the effectiveness of antiretroviral regimens.
Object: A systematic review of LPS as a marker of immune activation in HIV-1 infected patients.
Data sources: MEDLINE register of articles and international conference proceedings.
Review methods: Case–control studies comparing the role of plasma LPS as a marker of immune activation in
HIV-infected patients versus HIV negative subjects.
Data synthesis: Two hundred and six articles were selected using MEDLINE, plus 51 studies presented at
international conferences. Plasma LPS is a marker of immune activation in HIV-infected patients, determining the
entry of central memory CD4+ T cells into the replication cycle and finally generating cell death. Plasma LPS
probably results from immune-mediated alterations of the intestinal barrier, which can occur soon after HIV
seroconversion. LPS is a likely marker of disease progression, as it drives chronic monocyte activation, and some
studies suggest that hyperexpression of CCR5 receptors, related to LPS plasma levels, could be responsible for
monocyte trafficking in the brain compartment and for the appearance of HIV-associated neurocognitive disorders.
Long-term combination antiretroviral therapy (cART) generally reduces LPS concentrations, but rarely to the same
levels as in the control group. This phenomenon probably depends on ongoing but incomplete repair of the
mucosal barrier. Only in patients achieving maximal viral suppression (i.e. viral load < 2.5 cp/ml) are LPS levels
comparable to healthy donors. In successfully treated patients who did not restore CD4+ T cells, one hypothesis is
that the degree of residual microbial translocation, measured by LPS, alters the turnover of CD4+ T cells.
Conclusions: LPS is a marker of microbial translocation, responsible for chronic immune activation in HIV-infected
patients. Even in successfully treated patients, LPS values are rarely normal. Several studies suggest a role for LPS as
a negative predictive marker of immune restoration in patients with blunted CD4 T cell gain.Background
HIV-1 infection develops with acute viræmia and rapid
depletion of CD4 T cells within mucosal-associated
lymphoid tissues (MALT), particularly in gut lymphoid
compartments [1].
Lipopolysaccharide (LPS) is a component of the cell
wall of gram-negative bacteria and recent data show that
plasma LPS reflects microbial translocation in HIV-* Correspondence: m.vassallo@ch-cannes.fr
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reproduction in any medium, provided the orinfected patients [2]. Indeed, HIV-induced disruption of
MALT results in translocation of microbial products
across the intestinal mucosa into the peripheral circulation,
producing high levels of plasma LPS and bacterial DNA
that persist throughout chronic HIV infection [1,3].
The degree of microbial translocation has been associated
with HIV progression [4,5]. Despite successful virological
control under combination antiretroviral therapy (cART),
some patients do not restore their cellular immunity and
certain authors suggest a possible role for microbial trans-
location in persistent CD4T-cell depletion [6].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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role of plasma LPS as an immune activator in HIV-
infected patients and the impact of cART on LPS plasma
levels.
Methods
We obtained relevant articles from the Pubmed Mesh data-
base, using the broad search terms “Lipopolysaccharides”,
“HIV” and “Humans”.
We included studies regardless of date, language or
publication status.
In addition, we searched abstracts from the last three
Conferences on Retroviral and Opportunistic Infections
(CROI), i.e. 2010, 2011 and 2012, since interest in LPS
as an immune marker has been increasing over the past
three years.
Inclusion criteria were case–control studies evaluating
LPS plasma values in HIV-infected patients, compared
to those in healthy controls.
We selected 206 articles from Pubmed and 51 abstracts
from the past three CROI meetings describing the effect
of LPS on the human immune system or the impact of
cART on LPS.
Among the 206 articles selected in Pubmed, 203 were
written in English, 198 included an abstract and 132
focused more specifically on the immunological mechanisms
related to LPS. After examining these 132 articles in full
text, we retained 23 articles for their potential interest in
focusing more specifically on LPS as a marker of immune
activation or on the impact of cART on LPS. The remaining
articles were excluded as their content did not provide
further information with regard to the selected papers or
were not considered relevant. Figure 1 summarizes the
selection criteria for the articles.
Ethical approval
Wallet et al.: The protocol was approved by University
of Florida and University of South Florida/All Children’s
Hospital Institutional Review Boards.
Brenchley et al.: All human subjects gave informed
consent and all studies were approved by the appropriate
Institutional Review Boards or Animal Care and Use
Committees.
Redd et al.: Institutional Review Board approvals were
obtained from the Uganda National Council for Science
and Technology, and the Institutional Review Boards of
collaborating U.S. Institution (Walter Reed Army Institute
of Research, Columbia University, and John Hopkins
University).
Estes et al.: Animals were housed and cared in accord-
ance with American Association for Accreditation of
Laboratory Animal Care standards in AAALAC accredited
facilities, and all animal procedures were performed
according to protocols approved by the InstitutionalAnimal Care and Use Committees of the National Cancer
Institute, California National Primate Research Center or
Yerkes National Primate Research Center.
Jiang et al.: Theses studies were approved by the insti-
tutional review boards at the University Hospitals of
Cleveland, the National Institutes of Health, and the
University of California, San Francisco (UCSF), as well
as at participating AIDS Clinical Trials Unit sites.
Papasavvas et al.: Informed consent was obtained
according to the Human Experimentation Guidelines of
the US Department of Health and Human Services and
of the authors’ institutions. The study was approved by
the Institution Review Boards of the Wistar Institute
and Philadelphia FIGHT.
Munsaka et al.: The study was reviewed and approved
by the University of Hawaii Review Board.
Balagopal et al.: All subjects provided informed consent
for testing through a protocol approved by the Commit-
tees on Human Research of the John Hopkins School of
Medicine or Bloomberg School of Public Health.
For the other experimental researches cited in the text,
all patients provided written informed consent for use of
their blood samples under local institutional review
board approval.
Results
Increase of plasma LPS in HIV infected patients
Circulating LPS is likely to originate in the gastrointes-
tinal (GI) tract [2,7]. Epple et al. [8] compared gastro-
intestinal mucosal barrier function among 11 untreated,
8 suppressively-treated HIV-infected patients, and 9
HIV-seronegative controls, and found that HIV infection
induces intestinal barrier defect by mucosal CD4 T-cell
depletion, villous atrophy and alteration of tight-junction
protein composition. These alterations are mainly cytokine-
mediated, particularly via IL2, IL4 and TNF-alpha.
Estes et al. showed that microbial translocation is asso-
ciated with a breakdown of integrity of the intestinal epi-
thelial barrier of simian immunodeficiency virus (SIV)
infected rhesus macaques (RMs) [9]. The extent of mu-
cosal damage was correlated to the extent of microbial
translocation, thus generating the production of inflam-
matory cytokines and a dysfunction in the ability of
macrophages to phagocytose translocated microbial pro-
ducts. This phenomenon differs from other natural hosts
of SIV, such as African green monkeys (AGMs) and
Sooty mangabeys (SMs), who do not progress to AIDS
and in whom immune activation is minimal. Indeed,
authors found neither epithelial barrier breakdown nor
microbial products in the lamina propria of chronically
SIV-infected AGMs and SMs [9].
It is likely that mucosal damage in the gastrointestinal
tract of SIV-infected RMs and HIV-infected patients
leads to levels of microbial translocation that exceed the
Figure 1 Selection of articles.
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of persistent immune activation.Effects of chronic LPS stimulation in vivo
Plasma LPS triggers monocyte/macrophage activation,
generating the production of soluble CD14 (sCD14) and
pro-inflammatory cytokines (TNF, IL-1). The correlation
between plasma LPS levels and the frequency of circulating
CD8 T-cells with an activated CD38+ HLA-DR + pheno-
type suggests that microbial translocation might directly,
or indirectly via cytokines and chemokines, generate
polyclonal T-cell activation [2].
In a cross-sectional study comparing 227 HIV-infected
patients to 15 controls, Jiang et al. [10] showed that HIV in-
fection results in higher plasma levels of bacterial products
(LPS and bacterial 16S rDNA) and that these values were
correlated to T-cell activation markers (CD38 and HLA).
The authors suggest a model in which bacterial products
generate heightened expression of CD38 and HLA and
movement of central memory CD4+ T cells into the cell
cycle, finally resulting in cell death.
Indeed, Funderburg et al. recently showed that changes
in sCD14 levels correlate with changes in CD4 and central
memory CD4 T-cell cycling, suggesting that microbial
translocation may play a role in the turnover of central
memory CD4 cells in HIV infection [11].
Several studies [2,12,13] confirmed that LPS is a marker
of T-cell activation. D’Ettorre et al. [14] recently showed
that, in cART–treated subjects, the level of HIV-DNA in
the gut mucosa is correlated with levels of LPS and CD8 +
CD38+ T cells.
Some articles fail to show a correlation between LPS
and immuno-virological markers [1,15]. Wallet et al., for
example, conducted a longitudinal study on 14 healthy
and 33 perinatally HIV-1 infected patients, in whom LPS
levels were linked to monocyte/macrophage activation
markers but not to T-cell activation. The authors suggest
that microbial translocation affects monocyte/macro-
phage activation independently of lymphocyte activation
and HIV viral load.
Moreover, two recent works did not show any relation-
ship between microbial translocation and T-cell immune
activation, in HIV-infected children on successful cART
for Pilakka-Kanthikeel et al. [16] and in patients interrupt-
ing treatment for Papasavvas et al. [17].
HIV elite controllers (EC), defined as patients with
undetectable viral load (< 75 cp/mL) in the absence of
antiretroviral treatment, have higher plasma LPS and CD8+
T-cell activation levels than non-infected subjects, sug-
gesting that the early loss of CD4+ Tcells from the lamina
propria of the gastrointestinal tract and the physical
disruption of the mucosal barrier may contribute to gener-
alized T-cell activation [12].Lopez et al. [13] found that LPS in EC is positively
correlated with the activation of central-memory CD8+
T-cells and negatively with central-memory CD4+ T cells,
differing from successfully treated (ST) patients and
arguing against an indefinitely benign clinical status of EC.
Innate mechanisms to decrease effects of microbial
translocation
In order to reduce the inflammatory response due to
microbial translocation, at least two kinds of mechanisms
exist: first, clearance of LPS by the so-called endotoxin-
core antibodies (EndoCAb), which are produced by T-
dependent B-cells and play a major role, especially during
acute microbial translocation such as sepsis, by reducing
the amplitude of the inflammatory response. EndoCab
levels are also increased in chronic microbial translocation,
as occurs in inflammatory bowel disease as a part of
humoral response to LPS, but in chronic HIV infection
their levels are insufficient to neutralize circulating LPS
and prevent systemic immune activation, probably as a
consequence of B-cell dysfunction. Brenchley et al. found
that EndoCAb levels were higher in uninfected individuals
and in acute/early infected subjects than in HIV-infected
progressors [2].
The second mechanism to reduce the inflammatory
response is the functional impairment in monocytes,
generated by repeated stimulation of these cells by LPS.
This monocytic state is not a complete deactivation but
rather a specific reorientation in the reaction of the
cells to LPS, resulting in reduced production of pro-
inflammatory cytokines [18,19]. Typically seen during
acute conditions, e.g. sepsis, trauma or major surgery, it
can also be observed during chronic infections, as
shown by Brenchley et al., who found in HIV-infected
patients a significant inverse correlation between the
ability of monocytes to respond in vitro to LPS stimula-
tion and plasma levels of LPS [2].
Clinical consequences of immune activation
A study by Ancuta et al. suggests a role for elevated LPS
levels in driving monocyte activation in HIV disease pro-
gression [20], while Munsaka et al. [21] showed that
LPS-stimulation of monocytes in HIV-negative patients
augmented surface CCR5 expression from 21% to 99%,
increasing the risk for non-infected monocytes to become
infected.
Marchetti et al. showed that circulating LPS during
the initial years of chronic HIV infection is a strong pre-
dictor of disease progression independently of CD4 cell
count and HIV viræmia, suggesting its role as a bio-
marker for HIV disease monitoring [22].
Several studies showed that monocytes are the key
cells in the pathogenesis of HIV-associated neurocogni-
tive disorders, so that the hyper-expression of CCR5
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in HIV-infected patients if confirmed by other studies.
Indeed, in another study by Ancuta et al., plasma LPS levels
were higher in patients with HIV-associated dementia,
probably as a consequence of increased monocyte traf-
ficking in the brain [7].
Moreover, elevated LPS plasma levels increase the risk
of progression to chronic liver disease in hepatitis C-infected
patients, as LPS binds to Kupfer cells, up-regulating the
expression of proinflammatory and profibrogenic cytokinesFigure 2 Microbial translocation and CD4 cell depletion.such as tumor necrosis factor alpha (TNFα), interleukin 1
(IL-1), IL-6 and IL-12 [23].
Bellistri et al. [24] showed that increased microbial trans-
location is associated with a lack of early virological re-
sponse to HCV therapy in HIV-HCV co-infected patients.
Microbial translocation and macrophage activation
appear also to raise cardiovascular risks, as suggested by
Keledis et al., who showed that LPS and sCD14 are
associated with increases in the yearly rate of change
in carotid-intima thickness in HIV + patients [25].
Table 1 Microbial translocation and immunological outcomes in different populations of HIV-infected patients
(from all the selected articles included in this review)
LPS plasma values compared
to healthy donors
Main immunological outcomes
Untreated HIV + patients ++++ Chronic CD4 + T cell death, potential risk of accelerated disease progression
HIV + elite controllers +++ Unknown
HIV + successfully
treated patients
+/= Potential risk of for blunted CD4+ T cell gain. Only maximal virological suppression
(< 2.5 cp/ml) allows normalisation of LPS values
HIV + on treatment, with
persistent viral replication
++ Potential risk of blunted CD4+ T cell gain, to a higher extent than for
patients with viral control
Elite controllers: viral load < 75 cp/ml without the effect of cART.
Successfully treated patients: viral load < 40 cp/ml on cART.
Patients with viral replication: viral load > 40 cp/ml, on cART.
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ure increases procoagulant tissue factor expression on
monocytes of HIV-infected patients, suggesting a con-
tribution to coronary artery disease [26]. The main ex-
ception is the study conducted by Redd et al., who did
not find any correlation between microbial transloca-
tion and disease progression in a longitudinal cohort
study of HIV-1-infected African subjects, contrary to
the majority of American and European studies [3].
According to disease outcomes, the authors divided
patients into long-term nonprogressors, standard pro-
gressors and rapid progressors, finding no differences
in LPS and EndoCAb levels among these groups. One
explanation suggested by the authors is that the mode of
transmission may play a pivotal role, as studies examining
microbial translocation in the United States or Europe
concern male populations who most likely contracted the
infection through homosexual contact or intravenous drug
use, while the majority of African HIV-infected subjects
are heterosexual. Among other possible explanations for
these discordant results, it may be that different pre-
infection levels of EndoCab are linked to environmental
exposure to intestinal infections, or that different micro-
bial translocation markers are a symptom and not a cause
of disease progression [3].Table 2 Current knowledge on lipopolysaccharides and HIV-in
Accepted statements concerning LPS
1) Plasma values of LPS reflect microbial translocation
2) LPS is a marker of cellular activation, and probably of T-cell activation
3) Plasma values of LPS in HIV-infected patients derive from gut modification
dependent on mucosal cytokines
4) LPS levels generally decrease after initiation of cART, but rarely to the sam
in healthy subjects
Aspects of LPS that remain to be explained
1) Is microbial translocation a cause or a consequence of cellular activation?
2) Is gut disruption completely reversible after initiating cART?
3) Does LPS play a key role in virologically controlled patients with blunted CEffects of cART on microbial translocation
In general, long term cART has been associated with
reduced plasma LPS and immune activation markers.
However, LPS plasma levels often remain detectable in
successfully treated patients on cART, contrary to healthy
donors, as shown by Jiang et al. [10]. The authors suggest
that this phenomenon may be explained by ongoing
partial repair of the mucosal barrier.
Soon after initiation of cART (1, 8, and 48 weeks),
microbial translocation, immune activation markers and
plasma levels of HIV-RNA decrease consistently over
time, whereas CD4+ T-cell numbers increase. However,
repeated-measures analysis indicates that microbial
translocation decrease is independent of changes in
HIV-RNA levels [10]. Indeed, comparison between treated
and untreated patients with comparable levels of viræmia
showed that the first have lower levels of microbial trans-
location [10].
No association between microbial translocation and
CD4 T-cell count was observed, neither 1 week nor
8 weeks after starting cART, suggesting that the relationship
between microbial translocation and immune recovery is
more closely related to the cellular turnover linked to
chronic infection than to the initial rapid increase in circu-
lating CD4 T-cells after the introduction of cART [10].fection
Main articles
Jiang et al. [10], Ancuta et al. [7], Brenchley et al [2].
Hunt et al. [13], Jiang et al. [10]
, which is largely Epple et al. [8]
e values as Jiang et al. [10], Baroncelli et al. [6]
D4 cell gain?
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tion is associated with residual viral replication. Indeed,
comparison between 25 patients on cART with HIV viral
load values between 2 and 50 copies/ml and 19 subjects
with more complete suppression (i.e. < 2.5 cp/ml) showed
that only the second group attained the same levels of LPS
as HIV-uninfected subjects, suggesting that cART can
revert the HIV-induced gastrointestinal barrier defect that
is responsible for microbial translocation.
Of particular interest is the observation that treatment
interruptions not exceeding two months in one study
[6], three months in another [27], did not increase LPS
plasma levels, in contrast with immune activation markers
and viræmia.
In ST patients with blunted CD4+ T-cell gains, it has
been suggested that chronic immune activation and
increased cellular turnover, induced by such persistent
microbial translocation via the mechanisms described
above, might play a key role Figure 2 [10,12].
Bandera et al. confirmed that immunological non
responder patients have higher levels of LPS than full
responders and a higher proportion of Th17 cells, which
may be involved in the proinflammatory status of non
responders [28]. Similarly, Estes et al. suggested that a
preferential loss of GI tract Th-17 cells is linked to
persistent immune activation [9].
Tables 1 and 2 summarize current knowledge on LPS.
Conclusions
Plasma LPS is a marker of microbial translocation in
HIV-infected patients and its origin is probably a defective
intestinal barrier, where damage begins during the early
phase of HIV infection and continues during the chronic
period.
Mucosal damage and macrophage phagocytic dysfunc-
tional clearance of microbial products are responsible
for microbial translocation in blood.
Several studies indicate that microbial translocation is
associated with immune activation, with production of
sCD14 and pro-inflammatory cytokines.
There is increasing evidence that broad immune acti-
vation is an important driver of disease pathogenesis and
is responsible for CD4 T-cell depletion and HIV-related
co-morbid conditions. The main exception is a study by
Redd et al., who found little effect of microbial trans-
location on the rate of HIV-1 disease in African patients.
Authors explain that these results could be due to the
difference in patient characteristics, but they also suggest
that microbial translocation could be a symptom and
not a cause of disease progression.
Certain innate immune mechanisms counteract the
effect of microbial translocation, e.g. production of
antibodies to neutralize LPS activity and functional im-
pairment of macrophages when chronically stimulatedby LPS, but during HIV-infection these mechanisms
are generally insufficient to prevent systemic immune
activation.
The extent of microbial translocation is not correlated
to the viral load, as shown for example by Hunt and
Lopez, who found that even HIV EC display markers of
immune activation, suggesting that aviremic patients
also sustain GI tract damage that persists over time.
The introduction of cART reduces the degree of
microbial translocation, but in general not to the levels
observed among uninfected subjects. The mechanisms
of LPS reduction when starting cART are probably not
completely understood, as they do not depend on viral
load, but come into play very soon after treatment
initiation.
However, the lack of an association between reduced
microbial translocation and increased CD4 cell count
during the first weeks of treatment suggests that micro-
bial translocation has a greater impact on the cellular
turnover of latently infected cells than on circulating
CD4 T-cells.
The persistence of detectable levels of plasma LPS in
ST patients could be explained in at least three ways:
first, intestinal barrier repair is only partially achieved
with cART, suggesting that early treatment could be
more effective. Second, only regimens achieving maximal
viral suppression (i.e. < 2.5 cp/mL) allow complete nor-
malisation of the mucosal barrier. Third, LPS decrease
depends on complex immunological mechanisms, which
are only partially understood.
However, regardless of the causes of persistently high
LPS plasma levels in ST patients, there is increasing
evidence that microbial translocation could be respon-
sible for blunted CD4+ T-cell gains, by driving cellular
turn-over.
These results suggest that, in case of blunted CD4+
T cell gains despite successful cART, LPS could be used
as a negative predictor of immune restoration.
Further studies in primary HIV infection would be
helpful to find out if early introduction of cART, perhaps
with the use of the novel classes of antiretroviral agents
(integrase and entry inhibitors), could reduce mucosal
damage and avoid systemic immune activation during
the chronic phase, thus preventing further impairment
of immunological response.Competing interests
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